Bone Biologics Corporation

Equities

BBLG

US0980705018

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 17:06:43 05/07/2024 BST			5-day change	1st Jan Change
1.24 ^USD	+3.36%		+1.66%	-72.56%

06-20	Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion	CI
05-14	Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Bone Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 11, 2022 at 04:45 pm

Bone Biologics Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 0.469304 million compared to USD 0.491898 million a year ago. Basic loss per share from continuing operations was USD 0.05.
For the six months, net loss was USD 1.16 million compared to USD 0.923645 million a year ago. Basic loss per share from continuing operations was USD 0.11.

Latest news about Bone Biologics Corporation

Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion	06-20	CI
Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Certain Common Stock of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Certain Warrants of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Certain Stock Options of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Bone Biologics Corporation Reports Progress with NB1 Clinical Program	03-01	CI
Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Bone Biologics Corporation Announces Board Changes	01-11	CI
Bone Biologics Corporation Announces the Resignation of Erick Lucera as Director	01-02	CI
Bone Biologics' 1-for-8 Reverse Stock Split Takes Effect Wednesday	12-18	MT
Bone Biologics Closes Common Stock Offering; Shares Fall After Hours	11-20	MT
Bone Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Bone Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Top Midday Decliners	15/06/23	MT
Top Premarket Decliners	15/06/23	MT
Bone Biologics Prices Underwritten Public Offering of Common Stock	15/06/23	MT
Bone Biologics Files Registration for Planned Stock Offering at Target Price of $5.40 a Share	07/06/23	MT
Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Certain Warrants of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023.	05/04/23	CI
Certain Options of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023.	05/04/23	CI
Certain Common Stock of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023.	05/04/23	CI
Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Bone Biologics Corporation Auditor Raises 'Going Concern' Doubt	29/03/23	CI
Top Premarket Decliners	22/03/23	MT
Bone Biologics Corporation Resigns Stephen Laneve as Director	21/12/22	CI

Chart Bone Biologics Corporation

Duration

Period

More charts

Company Profile

Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Medical Devices & Implants

	1st Jan change	Capi.
BONE BIOLOGICS CORPORATION	-72.56%	1.32M
STRYKER CORPORATION	+11.67%	126B
SMITH & NEPHEW PLC	-1.99%	11.73B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-23.60%	6.62B
GLAUKOS CORPORATION	+52.03%	6.51B
INSPIRE MEDICAL SYSTEMS, INC.	-33.10%	3.98B
AXONICS, INC.	+8.40%	3.44B
ENOVIS CORPORATION	-20.83%	2.44B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-17.14%	1.88B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-21.05%	1.69B

Medical Devices & Implants